Navigation Links
Alfacell Provides Shareholder Update
Date:6/19/2009

e drug resistance (MDR). A publication regarding this study is in the process of being completed.

To quote Zbigniew Darzynkiewicz, M.D., Ph.D. Professor of Pathology and Medicine; Director, Brander Cancer Research Institute, New York Medical College, a long time collaborator who has published numerous peer reviewed articles regarding the molecular mechanism of Onconase states the following: "We now have compelling evidence from numerous preclinical studies including investigations on animals that Onconase strongly enhances effect of many types of anticancer drugs. The enhancement of the anticancer effectiveness by Onconase was shown to involve prevention of the induction defense mechanism which generally are triggered by the anticancer drugs and provide resistance to treatment. This propensity of Onconase makes it an attractive candidate to be used as an adjunct to variety of cancer treatment protocols. In this capacity Onconase can be widely used in therapy of different tumor types, including most common types such as cancer of breast, prostate, colon, ovary and lung."

Another quote is provided by Harvey I. Pass. Director, New York University Medical Center, Division of Thoracic Surgery; Chief of Thoracic Oncology: "The promising subgroup analysis requested by the FDA exhibiting a significant survival advantage for those individuals previously treated with chemotherapy who received the combination of Onconase and doxorubicin points to molecular mechanisms of inherent or acquired chemotherapy resistance. It is known that there are specific chemotherapy resistance genes which not only are present in untreated mesotheliomas but also become over expressed when certain chemotherapeutic agents, including platinum, are used in the first line therapy of cancer. These genes, known as the multidrug resistance (MDR) gene1 and the multidrug resistance associated protein gene make proteins which act like pumps to keep ch
'/>"/>

SOURCE Alfacell Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alfacell Provides ONCONASE(R) NDA Submission Update
2. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
3. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
4. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
5. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
6. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
7. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... MOINES, Iowa , Jan. 23, 2015  The Partnership to Fight ... Iowa health care leaders and a new study analyzing ... medications. The PFCD is a nationwide coalition working to educate policy ... research released at the Capitol was focused on how the ...
(Date:1/23/2015)... Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... therapies for operable and inoperable solid tumor cancers, announced today ... 7 th Annual Phacilitate Immunotherapy Forum in ... Phacilitate will take place on January 26 at 10:30 a.m. ...
(Date:1/23/2015)... , Jan. 23, 2015 More than a third of ... of those with private insurance, filled a prescription for an ... report in this week,s Morbidity and Mortality Weekly Report (MMWR). ... providers to treat moderate to severe pain.  They are also ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... Show 26% Partial Response, 63% Clinical Benefit ... ... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today announced that its lead ... Phase 2,trial when administered in combination with trastuzumab (Herceptin(R)) to,patients with ...
... Antitumor Activity Demonstrated in Metastatic Breast Cancer Patients, ... ENMD ), a clinical-stage pharmaceutical company developing,therapeutics ... today,announced the presentation of clinical data for the ... cancer. The data were presented by Bryan P.,Schneider, ...
Cached Medicine Technology:Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 2Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 4Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 5Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 6EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 2EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 3EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 4
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... a Boston based venture-backed technology startup has been ... Entrepreneurship Conference (WEC25). The WEC25 Expo is an ... products to a vast network of VCs and ... in the identity and access management industry to ...
... Feb. 4 Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ... for the first quarter of fiscal 2009, ended December 31, ... consolidated net loss of $7.6 million or $0.10 per share ... to revenues of $16.4 million and a consolidated net loss ...
... Hospitals of America (PHA) congratulates Congress on its ... healthcare access and insurance to millions of children ... "Congress recognized that the SCHIP bill was too ... address the contentious issue of physician ownership of ...
... Young Innovations, Inc.,(Nasdaq: YDNT ) today announced ... Sales for the fourth quarter of ... from the $25.0 million reported in the fourth quarter,of 2007. ... the,fourth quarter of 2007 to $4.8 million in the fourth ...
... LOS ANGELES, Feb. 4 The Elton John AIDS ... perform at the 17th Annual Elton John AIDS Foundation ... 2009, at the Pacific Design Center in Los Angeles. ... and David Furnish, and will be co-sponsored by Chopard, ...
... MedCath Corporation,(Nasdaq: MDTH ), a healthcare provider ... of cardiovascular disease,today announced its operating results for its first ... Highlights, -- Net revenue ... -- Adjusted EBITDA of $17.2 million, ...
Cached Medicine News:Health News:Delfigo Security Selected as One of Twenty Five Most Promising Startups by The Wharton Entrepreneurship Conference 2Health News:Delfigo Security Selected as One of Twenty Five Most Promising Startups by The Wharton Entrepreneurship Conference 3Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 2Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 3Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 4Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 5Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 6Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 7Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 8Health News:Physician Hospitals of America (PHA) Congratulates Congress on its Passage of a 'Clean' SCHIP Children's Health Bill 2Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 2Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 3Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 4Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 5Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 6Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 7Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 2Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 3Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 4Health News:MedCath Corporation Reports First Quarter Earnings 2Health News:MedCath Corporation Reports First Quarter Earnings 3Health News:MedCath Corporation Reports First Quarter Earnings 4Health News:MedCath Corporation Reports First Quarter Earnings 5Health News:MedCath Corporation Reports First Quarter Earnings 6Health News:MedCath Corporation Reports First Quarter Earnings 7Health News:MedCath Corporation Reports First Quarter Earnings 8Health News:MedCath Corporation Reports First Quarter Earnings 9Health News:MedCath Corporation Reports First Quarter Earnings 10Health News:MedCath Corporation Reports First Quarter Earnings 11Health News:MedCath Corporation Reports First Quarter Earnings 12Health News:MedCath Corporation Reports First Quarter Earnings 13Health News:MedCath Corporation Reports First Quarter Earnings 14
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: